Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
GSK-3 inhibitor 4
Cat. No.:
0225LY-1268
Appearance:
Solid
Purity:
≥98%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
GSK-3 inhibitor 4 is a brain-permeant, orally active triple inhibitor of CDK2, CDK5, and GSK-3 that can lower Tau protein levels, making it useful for Alzheimer's disease research.
Synonym:
2227279-83-4; 2-(4-fluoroanilino)-N-[4-(4-fluorophenyl)pyridin-3-yl]pyrimidine-4-carboxamide
CAS No.:
2227279-83-4
Compound CID:
134556675
Formula:
C22H15F2N5
Formula Weight:
403.38
Specification
Targets&IC50:
GSK-3β: 0.56 nM; GSK-3α: 0.45 nM; CDK5: 0.68 μM; CDK2: 0.47 μM
Relative Density:
1.401 g/cm3 at 20°C.
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
GSK-3 inhibitor 4 can be used in signaling pathway research to study the regulation of the Wnt/beta-catenin pathway.
Library Information
Target:
GSK-3; CDK
Receptor:
GSK-3; CDK2; CDK5
Pathways:
Wnt/β-Catenin signaling; Cell cycle; Transcription regulation; Stem cell regulation
Plate Number:
AOCL-17
Plate Location:
c5
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
50 mg/mL; 123.95 mM
